

12-20-2017

Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences

J. P. Mochel

Iowa State University, jmochel@iastate.edu

E. Tyden

Swedish University of Agricultural Sciences

K. Hellmann

Klifovet AG

J. C. Vendrig

Utrecht University

S. Senel

Hacettepe University

Follow this and additional works at: http://lib.dr.iastate.edu/bms_pubs



Part of the [Pharmacy Administration, Policy and Regulation Commons](#), and the [Veterinary Toxicology and Pharmacology Commons](#)

The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/bms_pubs/50. For information on how to cite this item, please visit <http://lib.dr.iastate.edu/howtocite.html>.

Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences

Abstract

The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. As a pan-European organisation it brings together pharmaceutical societies as well as academic, industrial, and regulatory scientists engaged in drug research and development, drug regulation, and education of professionals working in these fields.

EUFEPS represents pharmaceutical sciences in Europe and is recognised as such by both the European Commission and the European Medicines Agency. EUFEPS cooperates with the European Federation of Pharmaceutical Industries and other European organisations and maintains global connections with agencies such as the US Food and Drug Administration and the American Association of Pharmaceutical Scientists.

EUFEPS has established specified networks forming the basis of its activities. The creation of a Network on Veterinary Medicines is prompted by the manifold problems resulting from the use of veterinary drugs and its inherent interconnections with human medicine, environmental and public health. A long-term goal of this initiative is to expand the spectrum of available therapeutics for use in animals, including the development of innovative delivery systems.

Keywords

EUFEPS, Network, Veterinary Medicines, Pharmaceutical Sciences

Disciplines

Pharmacy Administration, Policy and Regulation | Pharmacy and Pharmaceutical Sciences | Veterinary Medicine | Veterinary Toxicology and Pharmacology

Comments

This is the peer reviewed version of the following article: Mochel, J. P., E. Tyden, K. Hellmann, J. C. Vendrig, S. Şenel, L. Dencker, R. T. Cristina, H. Linden, and I. Schmerold. "Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences." *Journal of veterinary pharmacology and therapeutics* (2017), which has been published in final form at doi: [10.1111/jvp.12472](https://doi.org/10.1111/jvp.12472). This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Authors

J. P. Mochel, E. Tyden, K. Hellmann, J. C. Vendrig, S. Senel, L. Dencker, R. T. Cristina, H. Linden, and I. Schmerold

Running title: EUFEPS NETWORK ON VETERINARY MEDICINES

**Network on Veterinary Medicines initiated by the European Federation For
Pharmaceutical Sciences**

J.P. Mochel^{a*}, E. Tyden^{b*}, K. Hellmann^{c*}, J.C. Vendrig^{d*}, S. Şenel^{e*}, L. Dencker^f,
R.T. Cristina^g, H. Linden^h, I. Schmerold^{i**}

^a *Department of Biomedical Sciences, Iowa State University College of Veterinary
Medicine, 1800 Christensen Drive, 50010 Ames, United States of America;*
jmochel@iastate.edu

^b *Department of Biomedical Science and Veterinary Public Health, Swedish University of
Agricultural Sciences, Division of Parasitology, Box 7036, 750 07 Uppsala, Sweden;*
eva.tyden@slu.se

^c *Klifovet AG, Geyerspergerstr. 27, 80689 München, Germany;*
klaus.hellmann@klifovet.de

^d *Utrecht University, Faculty of Veterinary Medicine, Institute for Risk Assessment
Sciences, Veterinary Pharmacology, Pharmacotherapy and Toxicology, Yalelaan 104,
Postbus 80152, 3584 CM Utrecht, The Netherlands; j.c.vendrig@uu.nl*

^e *Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology,
06100-Ankara, Turkey; ssenel@hacettepe.edu.tr*

^f *Department of Pharmaceutical Biosciences, Uppsala University Biomedical Centre, PO Box 591, SE-751 24 Uppsala, Sweden; lennart.dencker@farmbio.uu.se*

^g *Banat's University of Agriculture and Veterinary Medicine "King Michael I of Romania" from Timișoara; Faculty of Veterinary Medicine, Dept. of Pharmacology and Pharmacy, 119 Calea Aradului, 300645 Timișoara, Romania; rtcristina@yahoo.com*

^h *EUFEPS, Veddesta Business Center, SE-175 72 Järfälla (Stockholm), Sweden; hans.linden@eufeps.org*

ⁱ *University of Veterinary Medicine Vienna, Vienna, Austria. Permanent address: Marchetstr. 50/2/9, 2500 Baden, Austria; ivo.schmerold@vetmeduni.ac.at*

*Authors contributing to an equal extent to the manuscript

** Corresponding author. Mob.: 0043 664 2436018

E-mail address: ivo.schmerold@vetmeduni.ac.at

ABSTRACT

The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. As a pan-European organisation it brings together pharmaceutical societies as well as academic, industrial, and regulatory scientists engaged in drug research and development, drug regulation, and education of professionals working in these fields.

EUFEPS represents pharmaceutical sciences in Europe and is recognised as such by both the European Commission and the European Medicines Agency. EUFEPS cooperates with the European Federation of Pharmaceutical Industries and other European organisations and maintains global connections with agencies such as the US Food and Drug Administration and the American Association of Pharmaceutical Scientists.

EUFEPS has established specified networks forming the basis of its activities. The creation of a Network on Veterinary Medicines is prompted by the manifold problems resulting from the use of veterinary drugs and its inherent interconnections with human medicine, environmental and public health. A long-term goal of this initiative is to expand the spectrum of available therapeutics for use in animals, including the development of innovative delivery systems.

Keywords: EUFEPS; Network; Veterinary Medicines; Pharmaceutical Sciences

There are currently many national or international organisations and societies devoted to promoting veterinary sciences as a whole. These include the World Organization for Animal Health (OIE), the Global Animal Medicines Association (Health for Animals), the World Veterinary Organisation, the World Small Animal Veterinary Association (WSAVA), the World Association for Advancement of Veterinary Parasitology (WAAVP), and the European Board of Veterinary Specialisation (EBVS) as well as the European College of Veterinary Pharmacology and Toxicology (ECVPT). A key prerogative of these organisations is to contribute toward improved animal health and animal welfare in conjunction with efforts to address various issues related to animal diseases and public health. In this publication, we report on a new Network of the European Federation for Pharmaceutical Sciences (EUFEPS) specifically focusing on all scientific aspects of veterinary pharmaceuticals related to preclinical research, pharmaceutical quality, clinical use, legislation and regulatory policy as well as education and academic training (Dencker *et al.*, 2016).

The European Federation for Pharmaceutical Sciences (EUFEPS)

EUFEPS is a pan-European organisation founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. It combines pharmaceutical societies and scientists engaged in drug research and development, drug regulation, policymaking and education of professionals in the field. As an independent organisation, it constitutes a platform to enable interdisciplinary collaborations that will lead to safe, effective, innovative, economic, and timely medicines (EUFEPS, 2016).

The European Commission recognises EUFEPS as an integrative body representing pharmaceutical sciences within Europe. Additionally, the European Medicines Agency (EMA) acknowledges EUFEPS as a neutral scientific resource providing independent

opinions on draft regulatory guidelines. EUFEPS works with other European organisations, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), to help identifying industrial needs and promoting education in the field of pharmaceutical sciences. Other initiatives include the New Safe Medicines Faster-project proposed at the EU 6th RTD Framework Programme for Research and Technological Development (Bjerrum & Linden, 2011). Bringing together European scientists from all disciplines within the pharmaceutical sciences is a main goal of EUFEPS.

EUFEPS plays an active role in all international discussions that relate to pharmaceutical sciences across the globe. It is recognised as a key stakeholder by the US Food and Drug Administration (FDA), and it works actively with its sister organisation, the American Association of Pharmaceutical Scientists (AAPS). Additionally, EUFEPS collaborates with the International Pharmaceutical Federation (FIP) and maintains close ties with many other international organisations in the field of pharmaceutical sciences (EUFEPS, 2016).

EUFEPS Networks

EUFEPS Networks and their steering committees primarily move EUFEPS scientific activities forward. Already established EUFEPS Networks include the Networks on Safety Sciences, Environment and Pharmaceuticals, NanoMedicine, Regulatory Science, PharmacoGenomics Research and Implementation (EPRIN), Bioavailability and Biopharmaceutics, and Systems Pharmacology (Table 1).

Approximate Space for Table 1

Through the establishment of a new Network on Veterinary Medicines, EUFEPS expands its array of existing Networks and its relevance in the area of veterinary pharmaceutical sciences. All EUFEPS Networks have the potential to be partners for future collaboration with the Network on Veterinary Medicines.

EUFEPS Networks could therefore significantly help solve many problems related to the availability and clinical use of therapeutics for farm and pet animals, such as antimicrobials and antiparasitic substances, and new drug administration forms, including the evaluation of user safety and potential ecologic effects. Moreover, the scientific background and experience of EUFEPS could be valuable for the assessment of ongoing regulatory issues and legal aspects, graduate and postgraduate education and training (Table 2).

Approximate space for Table 2

Ongoing issues related to veterinary medicines

In line with the “One Health” principle, a strong connection between human and veterinary medicine is essential. The Network on Veterinary Medicines within the EUFEPS framework will contribute to this objective in the future. In fact, many of the present or emerging problems and prospects of veterinary medicine are best initiated using the instruments of multidisciplinary communication and cooperation. Several “One Health”-foci are summarised in Tab. 3. Virtually all of these issues overlap with the activities of established EUFEPS Networks.

Approximate space for Tab. 3

Objects of the Network on Veterinary Medicines in summary

A long-term goal of the veterinary network is to leverage the various sets of expertise offered by the EUFEPS to expand the spectrum of therapeutics intended for use in animals, including immunological products, vaccines, novel therapies or innovative drug delivery systems.

The objectives of the veterinary network can be summarised as follows:

- Strengthening interactions between human, pharmaceutical and veterinary sciences, thus fostering interdisciplinary exchanges of expertise between these disciplines;
- Strengthening academic research in related disciplines to promote the emergence of new concepts, principles and mechanisms of action to develop innovative VMPs;
- Supporting the development of academic research and collaboration in the fields of veterinary and pharmaceutical sciences with particular regard to more efficient, safe, and innovative VMPs. All veterinary and pharmacy faculties, as well as other related disciplines, are expected to benefit from such network activities;
- Scientifically advancing technologies including *in silico*/mathematical approaches involved in the analysis of metabolomics and proteomics, drug residues monitoring and related screening techniques (Mochel *et al.*, 2013);
- Contributing to the control of regulated therapeutics, including growth-promoters and substances derived from genetic editing. This is also true for international standards, guidelines and rules that apply to sport animals. Achieving this goal requires international cooperation with and between the official bodies

involved in regulating and controlling the marketing and use of VMPs, as well as the involvement of international anti-doping organisations;

- Encouraging and supporting education, training and continuing professional education for future healthcare professionals working in veterinary and pharmaceutical practice, academia or industrial research and development.

It is a further goal of this new Network to encourage the European Commission to initiate calls for research in the area of veterinary medicines, under, for instance, Horizon 2020, and forming strong consortia for application to funding opportunities (IMI, EU-funding).

Conflict of interest statement

None of the authors of this paper has a financial or personal relationship with other people or organisations that could inappropriately influence or bias the content of the paper.

References

- Bjerrum, O. J. & Linden, H. H. (2011). European new safe and innovative medicines initiatives: history and progress. In: B. H. Littmann & C. H. Jones (eds), *Translational Medicine and Drug Discovery*, pp. 265–287. University Press, Cambridge.
- Kaplan, R. M. & Vidyashankarb, A. N. (2012). An inconvenient truth: Global warming and anthelmintic resistance. *Veterinary Parasitology*, 186, 70-78
- Cezar, A. S., Toscan, G., Camillo, G., Sangioni, L. A., & Ribas, H. O. & Vogel, F.S.F. (2010). Multiple resistance of gastrointestinal nematodes to nine different drugs in a sheep flock in southern Brazil. *Veterinary Parasitology*, 173, 157–160.
- Dencker, L., Hellmann, K., Mochel, J., Şenel, S., Tyden, E., Vendrig, J. C., Linden, H. & Schmerold, I. (2016). Position Paper: EUFEPS Network on Veterinary Medicines Initiative: An interdisciplinary forum to support Veterinary Pharmacology and promote the development of new pharmaceuticals for Animal Health. *European Journal of Pharmaceutical Sciences*, 91, I-VII.
- Directive 2013/55/EU of the European Parliament and of the Council of 20 November 2013 amending Directive 2005/36/EC on the recognition of professional qualifications and Regulation (EU) No 1024/2012 on administrative cooperation through the Internal Market Information System ('the IMI Regulation'). *Official Journal of the European Union* L 354, December 28, 2013, 132-169.
- ECDC, EFSA, EMA (2015). ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. Stockholm/Parma/London: ECDC/EFSA/EMA, 2015. *EFSA Journal* 2015, 13(1):4006, 1-114. doi:10.2903/j.efsa.2015.4006

- EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control) (2017). The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2015. *EFSA Journal* 2017, 15(2):4694, 1-212. doi: 10.2903/j.efsa.2017.4694.
- EMA (2014). Revised policy for classification and incentives for veterinary medicinal products indicated for minor use minor species (MUMS)/limited market. Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/09/WC500172928.pdf
- EMA (2016). Developing a framework of collaboration between the European Medicines Agency (EMA) and academia. Report EMA/424858/2016. Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211452.pdf
- EUFEPS (2016). Retrieved from <http://www.eufeps.org/>
- European Commission, 2014. Proposal for a Regulation of the European Parliament and of the Council on veterinary medicinal products. Retrieved from <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52014SC0273&from=EN>
- Gill J. H., Kerr, C. A., Shoop, W. L. & Lacey, E. (1998). Evidence of multiple mechanisms of avermectin resistance in *haemonchus contortus* - comparison of selection protocols. *International Journal for Parasitology*, 28, 783-789.
- Kaplan, R. M. & Vidyashankarb, A. N. (2012). An inconvenient truth: Global warming and anthelmintic resistance. *Veterinary Parasitology*, 186, 70–78.
- Kümmerer, K. (2003). Significance of antibiotics in the environment. *Journal of Antimicrobial Chemotherapy*, 52, 5-7.

- Mochel, J. P., Gabrielsson, J., Collard, W., Fink, M., Gehring, R., Laffont, C., Liu, Y., Martin-Jimenez, T., Pelligand, L., Steimer, J.-L., Toutain, P.-L., Whittam, T. & Riviere, J. (2013). Animal health modelling & simulation society: a new society promoting model-based approaches in veterinary pharmacology. *Journal of Veterinary Pharmacology and Therapeutics*, 36, 417-419. doi: 10.1111jvp.12060
- OIE (2015). OIE List of antimicrobial agents of veterinary importance. Retrieved from <http://www.oie.int/doc/ged/D9840.PDF>
- Vallat, B. (2015). Feeding the world better by controlling animal diseases. Retrieved from <http://www.oie.int/for-the-media/editorials/detail/article/feeding-the-world-better-by-controlling-animal-diseases/>
- WHO (2017). Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Retrieved from <http://apps.who.int/iris/bitstream/10665/255027/1/9789241512220-eng.pdf?ua=1>
- Xi, C., Zhang, Y., Marrs, C. F., Ye, W., Simon, C., Foxman, B., & Nriagu, J. (2009). Prevalence of antibiotic resistance drinking water treatment and distribution systems. *Applied and Environmental Microbiology*. doi:10.1128/AEM.00382-09.

Table 1: Present EUFEPS Networks ^a. All Networks inherently constitute a positive setting for research, development and evaluation of veterinary pharmaceuticals

Network	Scope and aim
Bioavailability and Biopharmaceutics	Biopharmaceutics form the bedrock of many of the activities of the societies contributing to the EUFEPS ("Member Societies"). The activities of this network have provided important opportunities to assist the legislature in defining a harmonised approach across Europe (e.g., bioavailability and bioequivalence guidelines). Efforts focus on scientific questions which arise from poorly understood areas.
PharmacoGenomics Research and Implementation	This Network provides a platform focusing on research and how to best apply findings and learning in practice. This includes collaborative contributions to personalised medicines or precision medicine by promoting pharmacogenetic/genomic knowledge and expertise in establishing clinical evidence for safe and effective medicines and treatments using medication, based on a patient's genetic or other predisposition.
Environment and Pharmaceuticals	This Network addresses scientific achievements and discusses various issues related to pharmaceutical exposure in the environment, including attempts towards global harmonisation.
NanoMedicine	This Network focuses on pharmaceutical and biomedical sciences and the diagnostic and therapeutic aspects of nanomedicine, primarily in cooperation with related nanotechnology fields.

Quality by Design (QbD) and Process Analytical Technology (PAT) Sciences	This Network powers science-based process understanding and quality-by-design for medicines. It also contributes to education and training in the field and fosters hands-on implementation of systems approaches and emerging technologies in pharmaceutical production processes.
Regulatory Science	This Network offers academic, industrial and regulatory professionals in the various scientific fields brainstorming meetings, workshops and discussions on strategic goals and key issues in translational research covered by the pharmaceutical sciences.
Safety Sciences	This Network is dedicated to the development of safety sciences for medicines. It has organised several workshops focusing on education and training for safety scientists. The European Innovative Medicines Initiative (IMI) education and training project on safety sciences stems from this Network and is still on-going.

^a Their common aims lie in the promotion of scientific collaboration, cooperation and coordination, support of joint activities and engagement in education and training. Thus, forums for academic, industrial and regulatory professionals in respective scientific fields have been developed. Systems Pharmacology is an emerging new Network, as is the one proposed in this article – Veterinary Medicines (quoted from Dencker *et al.* (2016)). Reprinted from European Journal of Pharmaceutical Sciences 91, L. Dencker, K. Hellmann, J. Mochel, S. Şenel, E. Tyden, J.C. Vendrig, H. Linden, I. Schmerold, Position Paper: EUFEPS Network on Veterinary Medicines Initiative: An interdisciplinary forum to support Veterinary Pharmacology and promote the development of new pharmaceuticals for Animal Health, I–VII, Copyright (2016), with permission from Elsevier.

Table 2: Conceivable scientific exchange of the Network on Veterinary Medicines with established EUFEPS Networks

Relevant issues of the Network for Veterinary Medicines	Suitable Networks for joint activities
Strengthening interactions between medical, pharmaceutical and veterinary sciences	Quality by Design (QbD) and Process Analytical Technology (PAT) Sciences Regulatory Science Safety Sciences
Strengthening academic research (new concepts, principles and mechanisms of action); development of innovative new VMPs including innovative delivery systems	NanoMedicine PharmacoGenomics Research and Implementation
Novel individualised medication; legal (and illegal) use of pharmaceuticals (including growth-promoting compounds)	PharmacoGenomics Research and Implementation Regulatory Science Safety Sciences
Analysis of metabolomics and proteomics, veterinary drug residue monitoring	Safety Sciences

	Bioavailability and Biopharmaceutics;
Ecotoxicity of VMPs (fate and biological activity of the VMP ingredients and metabolites excreted via urine or faeces in the environment)	Environment and Pharmaceuticals
Veterinary drug regulatory processes (assessment, authorisation, supervision of VMPs); strategy discussion, science policy	Regulatory Science
Education and training of healthcare professionals in veterinary practice, pharmacy, or industrial research	All EUFEPS Networks

Table 3: Continuing issues related to Veterinary Medicine

Thematic area	Case example	Remarks	Problem	Reference
One health paradigm	Common use of pharmaceutical substances in human and veterinary medicine	All classes of antibacterial substances used in veterinary medicine are also registered for use in human medicine	3 rd and 4 th generation cephalosporins, quinolones, macrolides and polymyxins have been categorized as “Highest Priority Critically Important Antimicrobials” for Human Use by the WHO	WHO, 2017
Public health Environment	Only food derived from healthy animals can ensure safe and edible livestock products	Animal diseases are expected to reduce global production of food animals by more than 20%	Spread of (zoonotic) bacteria conveying antimicrobial resistance genes, drug residues in animal edible tissues and products, or the presence of veterinary antibiotics in soil and water	Vallat, 2015; EFSA and ECDC, 2017; Kümmerer, 2003; Xi <i>et al.</i> , 2009

<p>Development of new therapeutic strategies</p>	<p>The global emergence and spread of antimicrobial resistance are a threat to effective prevention and treatment of infectious diseases</p>	<p>Sales data from 26 EU/EEA countries in 2012 amount to 7982.0 tons of antimicrobials used in food-producing animals; this is twice the amount of antibiotics reported for human medicine</p>	<p>New pharmacological, biological or alternative approaches are needed to reduce the overall use of antibacterials in animals</p>	<p>ECDC/EFSA/EMA, 2015; EMA, 2014; EMA, 2016</p>
	<p>Parasitic helminths become increasingly insensitive to a wide array of anthelmintic drugs</p>	<p>Since the introduction of ivermectin in 1981, no novel anthelmintic drug class has been developed for use in livestock or horses, except for monepantel</p>	<p>Widespread antiparasitic resistance to benzimidazoles, tetrahydropyrimidines, and macrocyclic lactones in developing countries</p>	<p>Gill <i>et al.</i>, 1998; Cezar <i>et al.</i>, 2010; Kaplan & Vidyashankarb, 2012</p>

Regulatory issues	The complex regulatory framework regulating Veterinary Medicinal Products is presently being revised	The EMA has recently launched an initiative to develop a framework for stronger collaboration between pharmaceutical industry and academia	Several issues related to pharmaceutical research and development in human and veterinary medicine can only be solved by interdisciplinary and transparent cooperation	EMA, 2016; European Commission, 2014
Postgraduate training	Modern teaching techniques are invaluable tools for the continuous education of veterinary professionals	Topics of significance may differ from those developed in a more standard academic curriculum and could include strategies for finding and developing promising pharmacological candidates for use in animals	Continuous professional development should cover technical, scientific, regulatory and ethical developments and motivate professionals to participate in lifelong learning relevant to their profession	Directive 2013/55/EU